4.5 Article

Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization

期刊

BMC MUSCULOSKELETAL DISORDERS
卷 15, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2474-15-291

关键词

Selective androgen receptor modulator; Immobilization; Muscle wasting; Anabolism

向作者/读者索取更多资源

Background: Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators (SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle function and potentially translated into the clinical space. Methods: GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb immobilization. Results: GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling experiments using H-1-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation of cellular bioenergetic processes. Conclusions: Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for, at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis

Nicolas Desroy, Christopher Housseman, Xavier Bock, Agnes Joncour, Natacha Bienvenu, Laetitia Cherel, Virginie Labeguere, Emilie Rondet, Christophe Peixoto, Jean-Marie Grassot, Olivier Picolet, Denis Annoott, Nicolas Triballeau, Alain Monjardet, Emanuelle Wakselman, Veronique Roncoroni, Sandrine Le Tallec, Roland Blanque, Celine Cottereaux, Nele Vandervoort, Thierry Christophe, Patrick Mollat, Marieke Lamers, Marielle Auberval, Boska Hrvacic, Jovica Ralic, Line Oste, Ellen van der Aar, Reginald Brys, Bertrand Heckmann

JOURNAL OF MEDICINAL CHEMISTRY (2017)

Article Chemistry, Medicinal

Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial

Frederic Labeguere, Sonia Dupont, Luke Alvey, Florilene Soulas, Gregory Newsome, Amynata Tirera, Vanessa Quenehen, Thi Thu Trang Mai, Pierre Deprez, Roland Blanque, Line Oste, Sandrine Le Tallec, Steve De Vos, Annick Hagers, Ann Vandevelde, Luc Nelles, Nele Vandervoort, Katja Conrath, Thierry Christophe, Ellen van der Aar, Emanuelle Wakselman, Didier Merciris, Celine Cottereaux, Cecile da Costa, Laurent Saniere, Philippe Clement-Lacroix, Laura Jenkins, Graeme Milligan, Stephen Fletcher, Reginald Brys, Romain Gosmini

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Chemistry, Medicinal

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis

Franck Brebion, Romain Gosmini, Pierre Deprez, Marie Varin, Christophe Peixoto, Luke Alvey, Helene Jary, Natacha Bienvenu, Nicolas Triballeau, Roland Blanque, Celine Cottereaux, Thierry Christophe, Nele Vandervoort, Patrick Mollat, Robert Touitou, Philip Leonard, Frederic De Ceuninck, Iuliana Botez, Alain Monjardet, Ellen van der Aar, David Amantini

Summary: GLPG1972/S201086 is a potent and selective ADAMTS-5 inhibitor obtained through optimization of a promising hydantoin series. The compound has shown biochemical activity against rat and human ADAMTS-5, and demonstrated anticatabolic and anticatabolic activity.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Orthopedics

Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5

P. Clement-Lacroix, C. B. Little, M. M. Smith, C. Cottereaux, D. Merciris, S. Meurisse, P. Mollat, R. Touitou, F. Brebion, R. Gosmini, F. De Ceuninck, I Botez, L. Lepescheux, E. van der Aar, T. Christophe, N. Vandervoort, R. Blanque, D. Comas, P. Deprez, D. Amantini

Summary: GLPG1972/S201086 is a potent, selective, and orally available ADAMTS5 inhibitor that demonstrates significant protective efficacy on both cartilage and subchondral bone in preclinical OA models.

OSTEOARTHRITIS AND CARTILAGE (2022)

Article Cell Biology

IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases

Stephanie Lavazais, Manja Jargosch, Sonia Dupont, Frederic Labeguere, Christel Menet, Catherine Jagerschmidt, Frenz Ohm, Laszlo Kupcsik, Isabelle Parent, Celine Cottereaux, Florence Marsais, Line Oste, An Van de Water, Thierry Christophe, Steve De Vos, Padraic Fallon, Felix Lauffer, Philippe Clement-Lacroix, Kilian Eyerich, Reginald Brys

Summary: Innate immunity plays an important role in both environmental cue interpretation and adaptive responses, making modulators of innate immune responses potentially useful in treating immune-mediated inflammatory diseases. A selective IRAK4 inhibitor, GLPG2534, has been evaluated in various in vitro and in vivo models of inflammatory skin diseases, demonstrating inhibition of TLR and IL-1 responses in multiple cell types and dampening disease activity in murine models. Additionally, inhibiting IRAK4 reversed pathogenic molecular signatures in human lesional psoriasis and atopic dermatitis biopsies, highlighting its potential therapeutic strategy in chronic inflammatory skin diseases.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Endocrinology & Metabolism

Phasic production of urinary pyridinium crosslinks in mice:: The effect of ovariectomy

R Blanqué, C Cottereaux, CR Gardner

CALCIFIED TISSUE INTERNATIONAL (2001)

Article Biochemistry & Molecular Biology

Mechanisms involved in prostaglandin-induced increase in bone resorption in neonatal mouse calvaria

CR Gardner, R Blanqué, C Cottereaux

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2001)

暂无数据